Evidence map›Paper›PMID 35929135›Full record

Trial reportTechnology in cancer research & treatment

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.

Yuwen Qi, Yaxing Zhang, Yuying Shi, Shijie Yao, Mengyuan Dai, Hongbing Cai

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuwen Qi89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0000-0002-2420-2235
Yaxing Zhang89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Yuying Shi89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Shijie Yao89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0000-0003-4648-5464
Mengyuan Dai89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Hongbing Cai89674Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsHyperthermia, InducedOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHomologous RecombinationHumansHyperthermic Intraperitoneal ChemotherapyMutationNeoplasm Recurrence, LocalPlatinumSurvival RateAntineoplastic AgentsPlatinumEOCHIPECHRDHRRrecurrent ovarian cancer

Identifiers

PMID35929135
PMCPMC9358559
OpenAlexW4289860333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.